


Participant flow



Baseline characteristics

Table 1 Baseline patient and tumour characteristics

	All	LumA	LumB Her2-	LumB Her2+	Her2+	TN	P value (χ^2)
No. (row percentage)	692	372 (54)	198 (29)	64 (9)	17 (2)	41 (6)	
Age, years (range)^a	62 (24-92)	63 (24-92)	63 (31-90)	58 (34-91)	55 (25-73)	60 (29-83)	0.467
Mode of detection							0.001
Mammography screening	412 (60)	246 (66)	99 (50)	36 (56)	12 (71)	19 (46)	
Symptomatic presentation	280 (40)	126 (34)	99 (50)	28 (44)	5 (29)	22 (54)	
Tumour size (pT)^b							0.001
≤20 mm (pT1)	495 (72)	295 (79)	123 (62)	40 (63)	10 (59)	27 (66)	
>20-≤50 mm (pT2)	192 (28)	74 (20)	73 (37)	24 (38)	7 (41)	14 (34)	
>50 mm (pT3)	5 (1)	3 (1)	2 (1)	0 (0)	0 (0)	0 (0)	

Histological type							0.021
Ductal	554 (80)	284 (76)	155 (78)	61 (95)	16 (94)	38 (93)	
Lobular	88 (12)	58 (16)	29 (15)	1 (2)	0 (0)	0 (0)	
Other	50 (7)	30 (8)	14 (7)	2 (3)	1(6)	3 (7)	
Histological grade							<0.001
I	164 (24)	140 (38)	21 (11)	1 (2)	0 (0)	2 (5)	
II	314 (46)	214 (58)	80 (41)	10 (16)	4 (24)	6 (15)	
III	208 (30)	15 (4)	96 (49)	51 (82)	13 (76)	33 (81)	
Missing	6	3	1	2	0	0	
Multifocality							0.910
Absent	513 (75)	275 (74)	146 (76)	46 (73)	13 (77)	33 (81)	
Present	172 (25)	96 (26)	47 (24)	17 (27)	4 (24)	8 (20)	
Missing	7	1	5	1	0	0	
LVI							<0.001
Absent	515 (85)	298 (91)	141(80)	41(75)	10 (71)	30 (77)	
Present	90 (15)	28 (9)	35 (20)	14 (25)	4 (29)	9 (23)	
Missing	87	46	22	9	3	2	
Regional lymph node metastases (pN)^c							0.024
0	443 (64)	248 (67)	115 (58)	35 (55)	12 (71)	33 (81)	
1-3 (pN1)	199 (29)	100 (27)	66 (33)	21 (33)	4 (24)	8 (20)	
4-9(pN2)	36 (5)	18 (5)	10 (5)	8 (13)	0 (0)	0 (0)	
≥10 (pN3)	14 (2)	6 (2)	7 (4)	0 (0)	1 (6)	0 (0)	

Values in parentheses are column percentages rounded to the nearest whole number unless indicated otherwise.

^a Median (range), ^{b, c} According to the TNM classification for breast cancer

LVI Lymphovascular invasion

Outcome measures

Table 2 Multivariable logistic regression for prediction of axillary nodal status

	Axillary nodal status					
	N0 vs. N+ n=599		N1-2+ vs. N0 n=536		N≥ 3+ vs. N0 and N1-2+ n=599	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Subtype						
LumA	1.00	0.030	1.00	0.061	1.00	0.468
LumBHer2-	1.17 (0.75-1.83)		0.87 (0.54-1.42)		0.82 (0.41-1.64)	
LumBHer2+	1.11 (0.56-2.22)		0.86 (0.40-1.87)		1.44 (0.59-3.49)	
Her2+	1.49 (0.40-5.49)		0.65 (0.16-2.70)		0.80 (0.13-5.11)	
TN	5.09 (1.90-13.62)		0.16 (0.05-0.54)		0.37 (0.09-1.48)	
Age, per year	1.02 (1.00-1.04)	0.013	0.98 (0.96-1.00)	0.026	0.99 (0.96-1.01)	0.227
Mode of detection						
Symptomatic presentation	1.00	0.007	1.00	0.027	1.00	0.061
Mammography screening	1.73 (1.16-2.57)		0.61 (0.40-0.95)		0.57 (0.31-1.03)	
Tumour size, per mm	0.94 (0.92-0.96)	<0.001	1.05 (1.02-1.08)	<0.001	1.07 (1.04-1.11)	<0.001
Multifocality						
Present	1.00	0.015	1.00	0.066	1.00	0.051
Absent	1.72 (1.11-2.65)		0.64 (0.39-1.03)		0.54 (0.29-1.00)	
LVI						
Present	1.00	<0.001	1.00	<0.001	1.00	<0.001
Absent	4.62 (2.67-8.00)		0.28 (0.15-0.52)		0.21 (0.11-0.38)	

N0: Lymph node negative

N+: Any lymph node metastasis

N1-2+: Lymph node metastasis involving 1-2 nodes

N≥3+: Lymph node metastasis involving at least 3 nodes

LV Lymphovascular invasion

Adverse events

There were no adverse events associated with this trial.